ITMCTR2200005783尚未招募1 期
A randomized, comparison pharmacokinetic study of Jianpi Qushi Recipe and Febuxostat in Chinese hyperuricemia patients
Department of Immunity,the Tianjin FirstHospital,Tianjin,0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 性别
- All
入选标准
- •The standard age was 18-65 years old, with no gender limitation.The inclusion criteria met the diagnostic criteria set by Multidisciplinary Expert Consensus on diagnosis and Treatment of Hyperuricemia Related Diseases in China (2017) : for both men and women, fasting uric acid level exceeded 420µmol/L, which was called hyperuricemia.
排除标准
- •Secondary gout caused by kidney disease, blood disease, taking drugs, tumor radiation and chemotherapy, etc. In the acute onset of gouty arthritis; Caused by rheumatoid arthritis, psoriatic arthritis, bone tumors and other joint lesions; With serious pulmonary, cardiovascular, hematopoietic, central nervous system or other systemic diseases; Complicated with malignant tumor; Glutamic-pyruvic transaminase or glutamic-oxalacetic transaminase was 1.5 times higher than the upper limit of normal range; Serum creatinine was higher than the upper limit of normal range; Had undergone sex hormone replacement therapy and oral contraception in the past 3 months; Taking more than 10 mg/d of prednisone or other equivalent glucocorticoids; Or failing to take medication as prescribed. Pregnant or breast-feeding women or those who plan to become pregnant; Allergic to test drugs, weak physique or allergic constitution: those who meet any one of the above criteria can be excluded from the study.
研究者
相似试验
进行中（未招募）
1 期
A research study of how fast-acting insulin aspart works in the body of children, young people and grown-ups with type 1 diabetesDiabetes Mellitus, Type 1MedDRA version: 20.0Level: LLTClassification code 10045228Term: Type I diabetes mellitusSystem Organ Class: 100000004861EUCTR2017-002014-31-DEovo Nordisk A/S43
进行中（未招募）
1 期
A Randomized Double-blind study of Ustekinumab in Pediatric Subjects with Crohn's DiseaseModerately to severely active Crohn's diseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2016-001956-22-PLJanssen-Cilag International N.V.40
进行中（未招募）
1 期
A Randomized Double-blind study of Ustekinumab in Pediatric Subjects with Crohn's DiseaseEUCTR2016-001956-22-DEJanssen-Cilag International N.V.40
进行中（未招募）
1 期
A Randomized Double-blind study of Ustekinumab in Pediatric Subjects with Crohn's DiseaseModerately to severely active Crohn's diseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2016-001956-22-BEJanssen-Cilag International N.V.40
进行中（未招募）
1 期
A Randomized Double-blind study of Ustekinumab in Pediatric Subjects with Crohn's DiseaseModerately to severely active Crohn's diseaseMedDRA version: 19.1Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2016-001956-22-FRJanssen-Cilag International N.V.40